| P50 | author | Gideon Bollag | Q61518938 |
| | Barry S Taylor | Q88249464 |
| | Christine A Pratilas | Q102380741 |
| P2093 | author name string | Neal Rosen | |
| | Agnes Viale | |
| | Feng Xing | |
| | Weiqing Wang | |
| | James Tsai | |
| | Ensar Halilovic | |
| | David B. Solit | |
| | Madhavi Tadi | |
| | Yogindra Persaud | |
| | Poulikos I. Poulikakos | |
| | Paul B. Chapman | |
| | Eric W. Joseph | |
| P2860 | cites work | Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 |
| | Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways | Q24309037 |
| | Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism | Q24633458 |
| | Cluster analysis and display of genome-wide expression patterns | Q24644463 |
| | Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 |
| | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 |
| | Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 |
| | Linear models and empirical bayes methods for assessing differential expression in microarray experiments | Q27860758 |
| | Mutations of the BRAF gene in human cancer | Q27860760 |
| | Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 |
| | Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 |
| | PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo | Q28609356 |
| | BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 |
| | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 |
| | Mitogen-activated protein kinase pathways | Q29618431 |
| | The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. | Q34014364 |
| | Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. | Q34379673 |
| | PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling | Q35227481 |
| | Modulation of signalling by Sprouty: a developing story | Q35790325 |
| | Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma | Q36982042 |
| | Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression | Q37042015 |
| | Dual-specificity MAP kinase phosphatases (MKPs) and cancer | Q37106291 |
| | (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway | Q37112466 |
| | Genetic predictors of MEK dependence in non-small cell lung cancer | Q37113682 |
| | PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers | Q39859169 |
| | Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. | Q39874679 |
| | BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins | Q39954401 |
| | Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 |
| | Regulation of Raf-1 by direct feedback phosphorylation. | Q40467820 |
| | Paradoxical activation of Raf by a novel Raf inhibitor | Q40939473 |
| | Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma | Q42723115 |
| | A negative feedback signaling network underlies oncogene-induced senescence | Q43116108 |
| | Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers | Q43136770 |
| | Flow cytometric analysis of G1- and G2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements | Q44825483 |
| | BRAF and RAS mutations in human lung cancer and melanoma | Q78598197 |
| P433 | issue | 33 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 14903–14908 | |
| P577 | publication date | 2010-07-28 | |
| | 2010-08-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner | |
| P478 | volume | 107 | |